Brimonidine and timolol fixed-combination therapy versus monotherapy: A 3-month randomized trial in patients with glaucoma or ocular hypertension

E. Randy Craven, Thomas R. Walters, Robert Williams, Connie Chou, Janet K. Cheetham, Rhett Schiffman

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: The aim of this study was to compare the safety and intraocular pressure (IOP)-lowering efficacy of a fixed combination of brimonidine 0.2% and timolol 0.5% (fixed brimonidine/timolol) versus each drug used as monotherapy. Methods: Patients with glaucoma or ocular hypertension were randomized to receive fixed brimonidine/timolol BID (n = 385), brimonidine 0.2% TID (n = 382), or timolol 0.5% BID (n = 392) in a multicenter, double-masked study. The primary outcome measure was decrease from baseline IOP. Results: Over all follow-up measurements, the mean decrease from baseline IOP ranged from 4.9 to 7.6 mmHg with brimonidine/timolol, from 3.1 to 5.5 mmHg with brimonidine, and from 4.3 to 6.2 mmHg with timolol. Mean IOP reductions from baseline were significantly larger with fixed brimonidine/timolol than with timolol at all follow-up measurements (P ≤ 0.026); the difference was greater than 1.5 mmHg at 10 AM (peak effect for each treatment). Mean IOP reductions from baseline were significantly larger with fixed brimonidine/timolol than with brimonidine at 8 AM, 10 AM, and 3 PM (P < 0.001); the difference was greater than 1.5 mmHg. The rate of discontinuations owing to adverse events was 3.6% in the fixed timolol/brimonidine group. Conclusions: The fixed combination of brimonidine and timolol was well-tolerated and provided significantly better IOP control compared with either brimonidine or timolol used alone.

Original languageEnglish (US)
Pages (from-to)337-348
Number of pages12
JournalJournal of Ocular Pharmacology and Therapeutics
Volume21
Issue number4
DOIs
StatePublished - Aug 1 2005
Externally publishedYes

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Brimonidine and timolol fixed-combination therapy versus monotherapy: A 3-month randomized trial in patients with glaucoma or ocular hypertension'. Together they form a unique fingerprint.

Cite this